What Veracyte (VCYT) Said on Its Q3 Earnings Call
Veracyte (VCYT) narrowed its 2026 revenue forecast to $590M-$593M, down from $590M-$596M. It expects 16% Decipher Prostate revenue growth and raised Afirma revenue growth to 16%. For 2027, it anticipates 10% volume growth and mid-single-digit revenue growth. The company reported $40.3M in operating cash for Q3 and $370.5M in cash reserves. It plans to launch new tests for breast and bladder cancer.
How this was made
The 30-second read
Why it matters
The narrowed guidance and lowered revenue outlook suggest slower growth, likely leading to a modest sell‑off in the near term.
Market read
New guidance numbers are material for traders; the stock may see downside pressure as investors reassess growth expectations.
What to watch
Strong cash balance ($370.5M) and upcoming Medicare reimbursement for new tests may support longer‑term upside.
Background
Veracyte is a U.S. diagnostics company that provides genomic tests for various cancers. The article reports its Q3 earnings call and updated FY2026 guidance.
Ticker impact
Veracyte narrowed its FY2026 revenue guidance and lowered testing revenue forecasts, providing fresh guidance numbers.
potential modest decline as market prices in the lower outlook
Revenue guidance narrowed and growth expectations reduced; investors typically react negatively to slower guidance.
Market effects
Diagnostic genomics sector may see broader scrutiny as growth forecasts tighten.
U.S. biotech and healthcare indices could face slight pressure.
Limited to markets tracking U.S. biotech stocks.
Counterpoint
If the market overreacts, the guidance cut could be a buying opportunity given the company's cash position and upcoming product launches.
Key entities
- companyVeracyte
Diagnostics company providing genomic cancer tests.
